In response to an FDA request, Novartis has suspended U.S. marketing and sales of Zelnorm, a treatment for irritable bowel syndrome (IBS) with constipation and chronic constipation. This action is the result of a retrospective analysis of data from more than 18,000 patients in the clinical trial database, as well as an ongoing review involving a number of health authorities including the FDA. A public discussion and an advisory committee meeting is expected to take place to determine the risks a...